BeiGene Ltd Q3 2024 Earnings EPS of , Revenue Surpasses Estimates at 1.002 Billion
BGNE Stock | USD 206.16 14.05 7.31% |
About 54% of BeiGene's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding BeiGene suggests that some traders are interested. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
Total Revenue Achieved 1.002 billion in Q3 2024, surpassing the analyst estimate of 979.78 million, marking a 28 percent increase year-over-year.Net Product Revenu
Read at gurufocus.com
BeiGene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
BeiGene is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
IMVT | Immunovant | 5.78 | ||||
APLS | Apellis Pharmaceuticals | 4.63 | ||||
AKRO | Akero Therapeutics | 3.24 | ||||
PCVX | Vaxcyte | 2.77 | ||||
IONS | Ionis Pharmaceuticals | 1.50 | ||||
LEGN | Legend Biotech | 1.29 | ||||
ASND | Ascendis Pharma | 1.28 | ||||
IMAB | I Mab | 1.06 | ||||
ARWR | Arrowhead Pharmaceuticals | 1.03 | ||||
INCY | Incyte | 0.87 | ||||
BMRN | Biomarin Pharmaceutical | 0.83 | ||||
BPMC | Blueprint Medicines | 0.50 | ||||
KRYS | Krystal Biotech | 0.20 | ||||
TVTX | Travere Therapeutics | 1.89 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |